Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214935) titled 'A TQT Study of Effect of M2951 on Cardiac Repolarization' on Oct. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Condition:
Healthy
Intervention:
Drug: Placebo matched to M2951
Drug: Moxifloxacin
Drug: M2951 Low Dose
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 8, 2022
Target Sample Size: 36
...